ScreenerHero

GMAB Genmab A/S

NAS · US · Healthcare · Biotechnology · genmab.com
38.42USD-0.16%Mkt Cap: 24.01B $P/E: 30.30

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with rel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD
CORT
Corcept Therapeutics Incorporated
$13.19BUSDP/E 271.2

Key Statistics

Company
Market Cap24.01B USD
Enterprise Value24.51B USD
Revenue (TTM)4.13B USD
Gross Profit3.48B USD
Net Income (TTM)963.00M USD
Revenue/Share6.71 USD
Last Price38.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)30.30
P/E (Forward)22.71
PEG4.38
EV/EBITDA17.80
EV/Revenue5.93
P/S5.25
P/B3.48
EPS (TTM)1.27
EPS (Forward)1.53
52W Range
23.6289% of range40.17
52W High40.17 USD
52W Low23.62 USD
Profitability
Gross Margin93.60%
Oper. Margin35.24%
EBITDA Margin33.33%
Profit Margin25.89%
ROE16.47%
ROA7.48%
Growth
Revenue Growth24.90%
Earnings Growth-9.40%
Cash Flow & Leverage
Operating CF1.19B USD
CapEx (TTM)55.00M USD
FCF Margin21.08%
FCF Yield3.63%
Net Debt3.76B USD
Net Debt/EBITDA2.73
Balance Sheet
Debt/Equity0.93
Current Ratio2.46
Quick Ratio2.44
Book Value/Sh9.98 USD
Cash/Share2.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 1, 2018
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.05 USD
Upside (mean)+1.6%
Target Range32.00 USD – 45.00 USD
32.00+1.6% to mean45.00
# Analysts10
Ownership
Shares Out.624.06M
Float589.61M
Insiders0.00%
Institutions17.02%
Short Interest
Short Ratio2.2d
Short % Float0.81%
Short % Out.0.80%
Shares Short4.92M
Short (prev mo.)7.60M
Technical
SMA 5032.67 (+17.6%)
SMA 20029.63 (+29.7%)
Beta0.70
S&P 52W Chg14.58%
Avg Vol (30d)3.11M
Avg Vol (10d)3.61M
Technical Indicators
RSI (14)74.9
MACD1.0811
MACD Signal0.9638
MACD Hist.+0.1173
BB Upper37.30 USD
BB Middle34.50 USD
BB Lower31.70 USD
BB Width16.25%
ATR (14)1.208 USD
Vol Ratio (20d)4.67x